# Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia

> **NCT00836043** · — · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 6 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Alemtuzumab (MabCampath)

## Key facts

- **NCT ID:** NCT00836043
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Study terminated due to low enrollment.
- **Last updated:** 2013-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00836043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00836043, "Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00836043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*